Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02407808 · ClinicalTrials.gov registry record · Phase 1

Cannabinoids, Learning, and Memory

A Phase 1 study of Cannabis and Psychotic Disorders, sponsored by Yale University.

Active
Registry status
Phase 1
Development phase
80
Enrollment target
1
Study location

NCT02407808 is a Phase 1 study of Cannabis and Psychotic Disorders that is active but no longer recruiting, run by Yale University. The registered enrollment target is 80 participants, below the 107-participant average among 24 other Cannabis trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02407808, a Phase 1 study of Cannabis and Psychotic Disorders, is active but no longer recruiting, sponsored by Yale University.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

The overarching goal of this study is to characterize the effects of cannabinoids on working and episodic memory.

Interventions

  • DRUG Placebo
  • DRUG THC

Study Locations (1)

Connecticut

  • VA Connecticut Healthcare System - West Haven

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2015-02
Est. Completion 2025-12
Phase Phase 1

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT02407808

The ClinicalTrials.gov registry entry for NCT02407808 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 107-participant average among 24 other Cannabis trials with a reported enrollment target (25% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cannabis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02407808 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT02407808 about?

NCT02407808 is a clinical study titled "Cannabinoids, Learning, and Memory". The overarching goal of this study is to characterize the effects of cannabinoids on working and episodic memory.

What is the current status of trial NCT02407808?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2015-02. Estimated completion is 2025-12.

What conditions does trial NCT02407808 study?

This clinical trial studies the following conditions: Cannabis, Psychotic Disorders.

What interventions are being tested in trial NCT02407808?

The interventions under investigation include: Placebo (DRUG), THC (DRUG).

Who is sponsoring clinical trial NCT02407808?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02407808 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cannabis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.